All In Biotech

Drug Trial Radar · NCT06795022

First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours

A Modular Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD9793, a T Cell-engaging Antibody Targeting Glypican-3 (GPC3) in Adult Participants With Advanced or Metastatic Solid Tumours (RHEA-1)

Last checked: Nov 19, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

304

Planned (sponsor's estimate)

Start

Mar 27, 2025

Primary completion

Jun 30, 2027

Study completion Jun 30, 2028

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Jan 27, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This research is designed to determine if experimental treatment with AZD9793, a T cell-engaging antibody that targets GPC3, is safe, tolerable and has anti-cancer activity in patients with advanced or metastatic solid tumours which are GPC3+.

Conditions

  • Hepatocellular Carcinoma

Interventions

  • AZD9793 Intravenous (IV) monotherapyDrug

    T cell-engaging antibody that targets GPC3 on tumour cells

  • AZD9793 Subcutaneous (SC) monotherapyDrug

    T cell-engaging antibody that targets GPC3 on tumour cells

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The number of patients with adverse eventsTime frame: From first dose of study drug up to 30 days post last dose and prior to start of subsequent anticancer therapy
  2. The number of patients with serious adverse eventsTime frame: From first dose of study drug up to 30 days post last dose and prior to start of subsequent anticancer therapy
  3. The number of patients with adverse events of special interestTime frame: From first dose of study drug up to 30 days post last dose and prior to start of subsequent anticancer therapy
  4. The number of AEs leading to discontinuation of AZD9793Time frame: From first dose of study drug up to 30 days post last dose and prior to start of subsequent anticancer therapy
  5. The number of patients with dose-limiting toxicity (DLT), as defined in the protocol [Part A Dose Escalation only]Time frame: From date of first dose of study drug until the end of DLT evaluation period (up to 21, 28 or 35 days depending on dose regimen)
  6. Objective Response Rate (ORR) [Part B Dose Expansion only]Time frame: From first dose of study drug to progressive disease or the last evaluable assessment in the absence of disease progression whichever comes first (up to approximately 2 years)

Locations

21 sites in 7 countries. Site status is shown where the registry gives one.

  • Research Site

    La Jolla, California · Withdrawn

  • Research Site

    Los Angeles, California · Recruiting

  • Research Site

    Baltimore, Maryland · Not yet recruiting

  • Research Site

    Boston, Massachusetts · Not yet recruiting

  • Research Site

    St Louis, Missouri · Recruiting

  • Research Site

    Hackensack, New Jersey · Recruiting

  • Research Site

    Houston, Texas · Recruiting

  • Research Site

    Chengdu, China · Recruiting

  • Research Site

    Guangzhou, China · Recruiting

  • Research Site

    Harbin, China · Not yet recruiting

  • Research Site

    Shanghai, China · Recruiting

  • Research Site

    Pokfulam, Hong Kong · Recruiting

  • Research Site

    Shatin, Hong Kong · Recruiting

  • Research Site

    Kashiwa, Japan · Recruiting

  • Research Site

    Yokohama, Japan · Recruiting

  • Research Site

    Seoul, South Korea · Not yet recruiting

  • Research Site

    Seoul, South Korea · Recruiting

  • Research Site

    Barcelona, Spain · Not yet recruiting

  • Research Site

    Pamplona, Spain · Not yet recruiting

  • Research Site

    Taipei, Taiwan · Recruiting

  • Research Site

    Taoyuan, Taiwan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.